Compare Abbott Laboratories (ABT) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Apollo Global Management Ord Shs — how do they compare? Abbott Laboratories trades at $108.62 (market cap $187.95B), while Apollo Global Management Ord Shs trades at $141.71 (market cap $82.84B). The key difference: Abbott Laboratories is far larger — about 2.3× Apollo Global Management Ord Shs's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | APO | |
|---|---|---|
Market Cap | $187.95B | $82.84B |
Sector | Health | Financials |
52-Week High | $136.62 | $152.70 |
52-Week Low | $82.57 | $100.30 |
Enterprise Value | $214.96B | -$168.65B |
Dividend Yield | 2.32% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Apollo Global Management (APO) trades at $132.02, up 3.59% in 24 hours, with strong technical momentum as it approaches resistance near $134. The company reported mixed Q2 2026 earnings, missing EPS estimates but achieving record fee-related earnings of $785 million (Seeking Alpha, August 4, 2026). Fundamentals show robust revenue growth, with 2025 revenue at $32.05 billion, though net income margins have declined to 5.22% from prior peaks.
Outlook remains positive with an 82% analyst buy rating and a $151.50 price target, but risks include high P/E of 49.92 and exposure to private credit market volatility. Recent news highlights strategic AI infrastructure deals, such as a $2.6 billion partnership with Yankee Global Enterprises (Business Wire, August 11, 2026), supporting long-term growth amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
